Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anthera Pharmaceuticals IncANTH · Entity 163677 | Director | January 05, 2018 | January 09, 2018 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Financial Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anthera Pharmaceuticals Inc
Report date January 05, 2018 · Filed January 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05 | Direct | 84,705 |
Reported balance
After 2018-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05 | Direct | 84,705 |
Reported balance
After 2018-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017.
F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018.
BIOMARIN PHARMACEUTICAL INC
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,314 |
Reported balance
After 2026-03-17 transaction · row 1
1 source rowRow 1 · 2026-03-17 · Tax withholding · Disposed 2,117 · Balance 123,314 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 23, 2022 Filed Nov 29, 2022 02:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,500 | $99.50 | $348,250.00 |
DisclosureSEC source: 0001567619-22-020937 · doc1.xml · nonDerivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,847 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,500 | $67.81 | $237,335.00 |
DisclosureSEC source: 0001567619-22-020937 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 945 | $99.50 | $94,027.50 |
DisclosureSEC source: 0001567619-22-020937 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,847 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 934 | $95.09 | $88,814.06 |
DisclosureSEC source: 0001567619-22-020937 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,792 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 23:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,500 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-22-015384 · doc1.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,261 Underlying: Common Stock · 3,500 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 23:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,500 | $94.50 | $330,750.00 |
DisclosureSEC source: 0001567619-22-015384 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,726 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 23:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,500 | $67.81 | $237,335.00 |
DisclosureSEC source: 0001567619-22-015384 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 18:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,337 | $89.50 | $656,661.50 |
DisclosureSEC source: 0001567619-22-013907 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,726 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 19:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 576 | $83.92 | $48,337.92 |
DisclosureSEC source: 0001567619-22-013594 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,063 Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 9,762 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · derivative · entry 7 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,762 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,038 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · derivative · entry 6 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,038 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 9,762 | $84.50 | $824,889.00 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · nonDerivative · entry 5 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,639 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 9,762 | $37.46 | $365,684.52 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · nonDerivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,038 | $84.50 | $172,211.00 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,639 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,038 | $37.46 | $76,343.48 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| April 29, 2022 Filed May 6, 2022 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 340 | $62.41 | $21,218.38 |
DisclosureSEC source: 0001567619-22-009717 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,639 F1 · date: Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 01:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 582 | $80.72 | $46,979.04 |
DisclosureSEC source: 0001567619-22-007185 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,299 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 26,520 | $0.00 Strike: $78.27 | $0.00 |
DisclosureSEC source: 0001567619-22-007185 · doc1.xml · derivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,520 Underlying: Common Stock · 26,520 shares Expires 2032-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,868 | $78.27 | $146,208.36 |
DisclosureSEC source: 0001567619-22-007185 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,881 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007185 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,749 F1 · price: Restricted stock units granted on March 15, 2022. Price not applicable. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,072 | $87.77 | $94,089.44 |
DisclosureSEC source: 0001567619-22-002765 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,709 Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 00:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 576 | $83.46 | $48,072.96 |
DisclosureSEC source: 0001567619-21-012800 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,781 Read SEC document |
| May 07, 2021 Filed May 11, 2021 23:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 6,709 | $0.00 Strike: $28.23 | $0.00 |
DisclosureSEC source: 0001567619-21-009606 · doc1.xml · derivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,709 shares Expires 2021-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on January 29, 2021. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 07, 2021 Filed May 11, 2021 23:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,709 | $79.50 | $533,365.50 |
DisclosureSEC source: 0001567619-21-009606 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,357 F2 · date: Trade made pursuant to a 10b5-1 plan executed on January 29, 2021. Read SEC document |
| May 07, 2021 Filed May 11, 2021 23:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 6,709 | $28.23 | $189,395.07 |
DisclosureSEC source: 0001567619-21-009606 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on January 29, 2021. Read SEC document |
| April 30, 2021 Filed May 11, 2021 23:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 341 | $62.41 | $21,280.79 |
DisclosureSEC source: 0001567619-21-009606 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,357 F1 · date: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,692 | $76.30 | $434,299.60 |
DisclosureSEC source: 0001567619-21-007548 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,016 F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 29, 2021. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 516 | $78.52 | $40,516.32 |
DisclosureSEC source: 0001567619-21-006822 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,708 Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 01:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 582 | $77.21 | $44,936.22 |
DisclosureSEC source: 0001567619-21-006555 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,224 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 24,890 | $0.00 Strike: $78.39 | $0.00 |
DisclosureSEC source: 0001567619-21-006555 · doc1.xml · derivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,890 Underlying: Common Stock · 24,890 shares Expires 2031-03-14 F2 · date: Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 994 | $78.39 | $77,919.66 |
DisclosureSEC source: 0001567619-21-006555 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,806 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006555 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,800 F1 · price: Restricted stock units granted on March 15, 2021. Price not applicable. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,071 | $82.82 | $88,700.22 |
DisclosureSEC source: 0001567619-21-002227 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,673 Read SEC document |
| October 30, 2020 Filed Feb 12, 2021 20:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 17 | $62.59 | $1,063.96 |
DisclosureSEC source: 0001567619-21-003407 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,761 F1 · date: Represents shares acquired by the reporting person on October 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 13,230 | $0.00 Strike: $122.18 | $0.00 |
DisclosureSEC source: 0001567619-20-012731 · doc1.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,230 Underlying: Common Stock · 13,230 shares Expires 2030-06-28 F3 · date: Option grant vests 12/48th on June 29, 2021 and 1/48th on the 29th day of each month thereafter. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012731 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,744 F2 · price: Restricted stock units granted on June 29, 2020. Price not applicable. Read SEC document |
| April 30, 2020 Filed Jul 1, 2020 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 323 | $62.59 | $20,215.28 |
DisclosureSEC source: 0001567619-20-012731 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,104 F1 · date: Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 01:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 414 | $73.05 | $30,242.70 |
DisclosureSEC source: 0001567619-20-006974 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,781 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 9,600 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001567619-20-006637 · doc1.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · SVP, Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2030-03-15 F2 · date: Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006637 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · SVP, Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,195 F1 · price: Restricted stock units granted on March 16, 2020. Price not applicable. Read SEC document |
| March 13, 2020 Filed Mar 18, 2020 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,303 | $84.50 | $110,103.50 |
DisclosureSEC source: 0001567619-20-006637 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,465 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 01:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-002150 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · SVP, Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,768 F2 · price: Restricted stock units granted on February 3, 2020. Price not applicable. Read SEC document |
| October 31, 2019 Filed Feb 5, 2020 01:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9 | $62.23 | $560.06 |
DisclosureSEC source: 0001567619-20-002150 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,968 F1 · date: Represents shares acquired by the reporting person on October 31, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 30, 2019 Filed Jun 7, 2019 22:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 299 | $68.78 | $20,565.82 |
DisclosureSEC source: 0001567619-19-013091 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,959 F1 · date: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:12 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,953 | $94.00 | $277,582.00 |
DisclosureSEC source: 0001567619-19-008642 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,660 F1 · date: This trade is made pursuant to a 10b5-1 plan executed on March 12, 2019. Read SEC document |
| March 22, 2019 Filed Mar 27, 2019 00:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 415 | $88.05 | $36,540.75 |
DisclosureSEC source: 0001567619-19-007688 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,613 Read SEC document |
| March 15, 2019 Filed Mar 20, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 9,650 | $0.00 Strike: $94.53 | $0.00 |
DisclosureSEC source: 0001567619-19-007255 · doc1.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2029-03-14 F2 · date: Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2019 Filed Mar 20, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007255 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,028 F1 · price: Restricted stock units granted on March 15, 2019. Price not applicable. Read SEC document |
| March 15, 2019 Filed Mar 20, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,149 | $94.53 | $108,614.97 |
DisclosureSEC source: 0001567619-19-007255 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,248 Read SEC document |
| October 31, 2018 Filed Dec 20, 2018 22:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 22 | $68.78 | $1,513.20 |
DisclosureSEC source: 0001567619-18-008457 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,397 F1 · date: Represents shares acquired by the reporting person on October 31, 2018, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.